Table 4.
S-homocysteine concentrations at baseline in participants diagnosed with cardiovascular diseases during follow-up
| Diagnosis | No. of participants examined | S-homocysteine, μmol/l median (min–max) | P-valuea when compared to participants with no known cardiovascular disease |
|---|---|---|---|
| No known cardiovascular disease (hypertension disregarded) | 331 | 12.1 (2.9–48.3) | |
| Myocardial infarction | 26 | 15.1 (8.7–37.3) | <0.001 |
| Ischemic heart disease (angina pectoris) | 17 | 13.0 (7.3–25.6) | 0.24 |
| Aortic Aneurysm | 5 | 21.0 (10.7–24.2) | 0.02 |
| TIA or stroke | 18 | 11.7 (4.6–35.7) | 0.91 |
| Cardiac failure and/or arrhythmia | 32 | 13.2 (6.9–28.4) | 0.15 |
aMann–Whitney U-test